Previous slide
Next slide
The ProstaMetrix Platform Detects, Diagnoses, and Monitors Prostate Disease in a Single Doctor’s Visit
The Unmet Need
- Healthcare professional today are limited to a Digital Rectal Exam (DRE) to determine if the prostate is enlarged
- DREs are a subjective test and they do not provide a reproducible measurement of prostate volume
- PSA Tests have a 75% false positive rate and cannot be used on their own to accurately diagnose prostate disease
- Healthcare professionals today must use costly MRIs or invasive TRUS to determine the volume of the prostate
The ProstaMetrix Solution
Urologists believe that prostate volume is one of the best predictors of disease progression
Provides the ability to healthcare professionals to perform Quantitative Digital Rectal Exams (QDRE) to determine prostate volume
Allows for integration with the ProstaMetrix PSA Test to provide Prostate Density (PSAD) at the time of the initial doctor’s visit
- Proprietary data management system that tracks over time PSA, Prostate Volume, and PSAD, allowing allows practitioners and patients to monitor the progress of their disease
- Reduces the amount of unnecessary MRIs, TRUS, and biopsies, saving the healthcare system $10s of millions per year
- Preventing unnecessary intervention protects men against ED, incontinence, and other complications
The ProstaMetrix Value Proposition
